We are live on ! Find out more
DCMIC

Decheng Capital Management III (Cayman) Portfolio holdings

AUM $300M
1-Year Est. Return 15.74%
This Fund
S&P 500
This Quarter Est. Return
-32.13%
1 Year Est. Return
+15.74%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$264M
AUM Growth
-$62.5M
Cap. Flow
+$49.3M
Cap. Flow %
18.7%
Top 10 Hldgs %
83.14%
Holding
26
New
2
Increased
–
Reduced
–
Closed
1

Top Buys

Rank Stock Value
1
ZNTL icon
Zentalis Pharmaceuticals
ZNTL
+$48.3M
2
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$5.25M

Top Sells

Rank Stock Value
1
CMPI
Checkmate Pharmaceuticals, Inc. Common Stock
CMPI
+$4.25M

Sector Composition

Rank Sector Weight
1 Healthcare 99.28%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ZNTL icon
1
Zentalis Pharmaceuticals
ZNTL
$356M
$51.3M 19.44%
+1,824,583
New +$48.3M
ALPN
2
DELISTED
Alpine Immune Sciences Inc
ALPN
$40.1M 15.19%
4,708,288
– –
HLTH
3
DELISTED
Cue Health Inc. Common Stock
HLTH
$28.7M 10.9%
8,980,909
– –
ILMN icon
4
Illumina
ILMN
$29.3B
$28.4M 10.78%
158,557
– –
RCUS icon
5
Arcus Biosciences
RCUS
$3.56B
$22M 8.36%
869,790
– –
TXG icon
6
10x Genomics
TXG
$5.79B
$13.8M 5.22%
303,984
– –
ALBO
7
DELISTED
Albireo Pharma Inc
ALBO
$10.3M 3.9%
518,342
– –
EQ icon
8
Equillium
EQ
$134M
$9.07M 3.44%
4,447,308
– –
ACET icon
9
Adicet Bio
ACET
$74.1M
$8.47M 3.21%
36,250
– –
BYSI icon
10
BeyondSpring
BYSI
$35.8M
$7.14M 2.71%
4,958,142
– –
RXDX
11
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
$7.06M 2.68%
250,000
– –
WHWK
12
Whitehawk Therapeutics
WHWK
$232M
$6.48M 2.46%
526,329
– –
PACB icon
13
Pacific Biosciences
PACB
$363M
$6.47M 2.45%
1,463,872
– –
HZNP
14
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$4.42M 1.68%
+55,400
New +$5.25M
WGS icon
15
GeneDx Holdings
WGS
$2.08B
$4.31M 1.63%
103,604
– –
MRSN
16
DELISTED
Mersana Therapeutics
MRSN
$4.18M 1.58%
36,171
– –
AURA icon
17
Aura Biosciences
AURA
$799M
$2.98M 1.13%
210,000
– –
TERN
18
DELISTED
Terns Pharmaceuticals
TERN
$1.77M 0.67%
714,285
– –
OWLT icon
19
Owlet
OWLT
$158M
$1.53M 0.58%
64,171
– –
NBSE
20
DELISTED
NeuBase Therapeutics, Inc. Common Stock
NBSE
$1.05M 0.4%
50,000
– –
SCYX icon
21
SCYNEXIS
SCYX
$51.6M
$1.03M 0.39%
69,444
– –
NAUT icon
22
Nautilus Biotechnolgy
NAUT
$113M
$807K 0.31%
300,000
– –
MASS icon
23
908 Devices
MASS
$341M
$412K 0.16%
20,000
– –
OMIC
24
DELISTED
Singular Genomics Systems, Inc. Common Stock
OMIC
$76K 0.03%
667
– –
CMPI
25
DELISTED
Checkmate Pharmaceuticals, Inc. Common Stock
CMPI
– –
-1,333,254
Closed -$4.25M

Similar funds

IBT
International Biotechnology Trust London, United Kingdom $297M AUM 17.25% 1-Year Est. Return
3LCM
3D/L Capital Management Hartford, Connecticut $308M AUM 13.67% 1-Year Est. Return
DT
Daniels + Tansey Wilmington, Delaware $289M AUM 18.06% 1-Year Est. Return
SFG
Steward Financial Group Colleyville, Texas $315M AUM 13.78% 1-Year Est. Return
TFA
Triad Financial Advisors Greensboro, North Carolina $284M AUM 14.95% 1-Year Est. Return
AEPLI
AH Equity Partners LSV I Menlo Park, California $315M AUM 9.31% 1-Year Est. Return
CC
Chanos & Company New York $318M AUM 4.62% 1-Year Est. Return
KBC
Key Bridge Compliance $319M AUM

Decheng Capital Management III (Cayman)'s Q2 2022 Portfolio in Review

As of Q2 2022, Decheng Capital Management III (Cayman) held 26 positions worth $264M, down 19% from $326M the previous quarter. Its ten largest holdings account for 83% of the portfolio.

Decheng Capital Management III (Cayman) deployed $49.3M of net new capital in Q2 2022, opening 2 new positions. Its largest new stake was Zentalis Pharmaceuticals: 1,824,583 shares worth $51.3M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier.

On the sell side, the most notable exit was Checkmate Pharmaceuticals, Inc. Common Stock, an estimated $4.25M sold.

  • Decheng Capital Management III (Cayman)'s largest Q2 2022 buy was Zentalis Pharmaceuticals: 1,824,583 shares worth $51.3M.
  • Decheng Capital Management III (Cayman) fully exited Checkmate Pharmaceuticals, Inc. Common Stock in Q2 2022, selling an estimated $4.25M.
  • Decheng Capital Management III (Cayman)'s ten largest holdings make up 83% of its $264M portfolio in Q2 2022.
  • Decheng Capital Management III (Cayman) opened 2 new positions and closed 1 in Q2 2022.
  • Decheng Capital Management III (Cayman)'s portfolio value fell 19% quarter-over-quarter to $264M.

Based on Decheng Capital Management III (Cayman)'s 13F filing for Q2 2022, filed 1 Aug 2022.